Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$80.68 - $121.90
Previous CloseN/A
Volume168.58K
Average Volume (3M)1.11M
Market Cap
$5.67B
Enterprise Value$5.86B
Total Cash (Recent Filing)$102.01M
Total Debt (Recent Filing)$469.11M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
May 01, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding63,906,010
10 Day Avg. Volume1,051,929
30 Day Avg. Volume1,111,289
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.14
Price to Cash Flow (P/CF)-48.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.99
Enterprise Value/Ebitda-35.74
Forecast
1Y Price Target
$130.00Price Target Upside46.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Growth PotentialBPMC is seen as an attractive stock due to its overall beat-and-raise growth profile and limited competition in its commercial profile, with significant revenue potential.
Market OpportunityAyvakit has demonstrated steady growth since its first-in-disease ISM approval, driven in part by new patient starts and a broadening/deepening prescriber base.
Product DevelopmentWT KIT '808 oral pill presents potential upside as an oral blockbuster in multiple inflammatory indications, with early Phase 1 data viewed positively by investors.
Bears Say
Competitor RiskBears are concerned about Q1 risks and potential competitor data impacting BPMC's performance.
Pipeline ChallengesLonger-term, BLU-808 is not believed to be the solution, and Blueprint will need to replenish its pipeline with recent deprioritizations.
Uncertain Product FutureThe fate of BLU-808 (the urticaria product) seems uncertain, as it would need to become a viable, niche product among established medications.
---
Ownership Overview
1.56% Insiders
42.51% Mutual Funds
26.50% Other Institutional Investors
12.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $80.67 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Blueprint Medicines’s market cap is $5.67B.
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Feb 13, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.086.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -0.51.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,906,010 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went down -8.082%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Currently, no hedge funds are holding shares in BPMC
---
Blueprint Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.00 (46.53% Upside)
$130.00 (46.53% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 84.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.47%
12-Months-Change
Fundamentals
Return on Equity
-31.26%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corporation (BPMC) is a biopharmaceutical company focused on developing targeted therapies to improve the lives of patients with genomically defined cancers, rare diseases, and cancer immunotherapy. Operating within the biotechnology and pharmaceutical sectors, the company leverages its proprietary scientific platform to design and develop highly selective kinase inhibitors. Its core products include FDA-approved therapies such as AYVAKIT/AYVAKYT (avapritinib) for certain types of gastrointestinal stromal tumors (GIST) and systemic mastocytosis, as well as other investigational therapies in clinical development.
---
BPMC Company Deck
---
BPMC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong revenue growth and market expansion for AYVAKIT, successful international progress, promising development of BLU-808, and financial discipline. However, some challenges in Q1 2025 and a heavy reliance on the U.S. market were noted.Read More>---
BPMC Stock 12 Month Forecast
Average Price Target
$130.00
▲(46.53% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+11.00%
reiterated a buy rating last month
Copying Derek Archila's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +11.00% per trade.
---